vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and PACS Group, Inc. (PACS). Click either name above to swap in a different company.
PACS Group, Inc. is the larger business by last-quarter revenue ($1.4B vs $962.7M, roughly 1.4× APTARGROUP, INC.). APTARGROUP, INC. runs the higher net margin — 7.7% vs 4.4%, a 3.3% gap on every dollar of revenue. On growth, PACS Group, Inc. posted the faster year-over-year revenue change (18.4% vs 13.5%). Over the past eight quarters, PACS Group, Inc.'s revenue compounded faster (20.5% CAGR vs 2.6%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
ATR vs PACS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $962.7M | $1.4B |
| Net Profit | $74.3M | $59.7M |
| Gross Margin | — | — |
| Operating Margin | 11.0% | 7.0% |
| Net Margin | 7.7% | 4.4% |
| Revenue YoY | 13.5% | 18.4% |
| Net Profit YoY | -26.4% | 3022.5% |
| EPS (diluted) | $1.13 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $962.7M | $1.4B | ||
| Q3 25 | $961.1M | $1.3B | ||
| Q2 25 | $966.0M | $1.3B | ||
| Q1 25 | $887.3M | $1.3B | ||
| Q4 24 | $848.1M | $1.1B | ||
| Q3 24 | $909.3M | $1.0B | ||
| Q2 24 | $910.1M | $981.4M | ||
| Q1 24 | $915.4M | $934.3M |
| Q4 25 | $74.3M | $59.7M | ||
| Q3 25 | $127.9M | $52.4M | ||
| Q2 25 | $111.7M | $51.0M | ||
| Q1 25 | $78.8M | $28.5M | ||
| Q4 24 | $100.9M | $1.9M | ||
| Q3 24 | $100.0M | $15.6M | ||
| Q2 24 | $90.5M | $-10.9M | ||
| Q1 24 | $83.1M | $49.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 17.1% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.2% |
| Q4 25 | 11.0% | 7.0% | ||
| Q3 25 | 14.2% | 6.4% | ||
| Q2 25 | 14.9% | 6.2% | ||
| Q1 25 | 12.8% | 3.8% | ||
| Q4 24 | 14.2% | 1.7% | ||
| Q3 24 | 15.2% | 2.2% | ||
| Q2 24 | 13.8% | 0.1% | ||
| Q1 24 | 12.2% | 8.6% |
| Q4 25 | 7.7% | 4.4% | ||
| Q3 25 | 13.3% | 3.9% | ||
| Q2 25 | 11.6% | 3.9% | ||
| Q1 25 | 8.9% | 2.2% | ||
| Q4 24 | 11.9% | 0.2% | ||
| Q3 24 | 11.0% | 1.5% | ||
| Q2 24 | 9.9% | -1.1% | ||
| Q1 24 | 9.1% | 5.3% |
| Q4 25 | $1.13 | $0.42 | ||
| Q3 25 | $1.92 | $0.32 | ||
| Q2 25 | $1.67 | $0.31 | ||
| Q1 25 | $1.17 | $0.17 | ||
| Q4 24 | $1.48 | $-0.03 | ||
| Q3 24 | $1.48 | $0.10 | ||
| Q2 24 | $1.34 | $-0.07 | ||
| Q1 24 | $1.23 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $409.5M | $197.0M |
| Total DebtLower is stronger | $1.1B | $353.2M |
| Stockholders' EquityBook value | $2.7B | $946.8M |
| Total Assets | $5.3B | $5.6B |
| Debt / EquityLower = less leverage | 0.43× | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $409.5M | $197.0M | ||
| Q3 25 | $264.8M | $355.7M | ||
| Q2 25 | $169.8M | $294.2M | ||
| Q1 25 | $136.8M | $287.5M | ||
| Q4 24 | $226.2M | $157.7M | ||
| Q3 24 | $327.9M | $49.5M | ||
| Q2 24 | $223.9M | $73.4M | ||
| Q1 24 | $201.1M | $81.2M |
| Q4 25 | $1.1B | $353.2M | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | $411.9M | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — | ||
| Q1 24 | $680.4M | — |
| Q4 25 | $2.7B | $946.8M | ||
| Q3 25 | $2.8B | $871.3M | ||
| Q2 25 | $2.7B | $806.8M | ||
| Q1 25 | $2.5B | $750.2M | ||
| Q4 24 | $2.5B | $709.6M | ||
| Q3 24 | $2.5B | $660.0M | ||
| Q2 24 | $2.4B | $572.1M | ||
| Q1 24 | $2.3B | $128.0M |
| Q4 25 | $5.3B | $5.6B | ||
| Q3 25 | $5.1B | $5.6B | ||
| Q2 25 | $4.9B | $5.5B | ||
| Q1 25 | $4.5B | $5.5B | ||
| Q4 24 | $4.4B | $5.2B | ||
| Q3 24 | $4.6B | $4.5B | ||
| Q2 24 | $4.5B | $3.9B | ||
| Q1 24 | $4.4B | $3.9B |
| Q4 25 | 0.43× | 0.37× | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | 0.58× | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.7M | $-3.4M |
| Free Cash FlowOCF − Capex | $96.9M | — |
| FCF MarginFCF / Revenue | 10.1% | — |
| Capex IntensityCapex / Revenue | 9.0% | — |
| Cash ConversionOCF / Net Profit | 2.47× | -0.06× |
| TTM Free Cash FlowTrailing 4 quarters | $299.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.7M | $-3.4M | ||
| Q3 25 | $177.6M | $204.8M | ||
| Q2 25 | $126.0M | $52.6M | ||
| Q1 25 | $82.7M | $150.2M | ||
| Q4 24 | $178.2M | $64.6M | ||
| Q3 24 | $229.3M | $209.2M | ||
| Q2 24 | $143.6M | $34.8M | ||
| Q1 24 | $92.3M | $58.8M |
| Q4 25 | $96.9M | — | ||
| Q3 25 | $114.3M | — | ||
| Q2 25 | $62.5M | — | ||
| Q1 25 | $25.9M | — | ||
| Q4 24 | $112.2M | — | ||
| Q3 24 | $162.7M | — | ||
| Q2 24 | $75.4M | — | ||
| Q1 24 | $16.7M | — |
| Q4 25 | 10.1% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 6.5% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 1.8% | — |
| Q4 25 | 9.0% | — | ||
| Q3 25 | 6.6% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 6.4% | — | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 7.5% | — | ||
| Q1 24 | 8.3% | — |
| Q4 25 | 2.47× | -0.06× | ||
| Q3 25 | 1.39× | 3.91× | ||
| Q2 25 | 1.13× | 1.03× | ||
| Q1 25 | 1.05× | 5.28× | ||
| Q4 24 | 1.77× | 33.78× | ||
| Q3 24 | 2.29× | 13.39× | ||
| Q2 24 | 1.59× | — | ||
| Q1 24 | 1.11× | 1.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
PACS
Segment breakdown not available.
